You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
|
|---|---|
| Published in |
Journal of Experimental & Clinical Cancer Research, February 2014
|
| DOI | 10.1186/1756-9966-33-15 |
| Pubmed ID | |
| Authors |
Niels Eckstein, Lea Röper, Bodo Haas, Henrike Potthast, Ulrike Hermes, Christoph Unkrig, Frauke Naumann-Winter, Harald Enzmann |
| Abstract |
Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research [CA Cancer J Clin63:11-30]. About a decade ago, the arms race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors (TKI) into pharmacological anti-cancer therapy. According to their molecular mechanism of action, TKI in contrast to so-called "classic" or "conventional" cytostatics belong to the group of targeted cancer medicines, characterized by accurately fitting with biological structures (i.e. active centers of kinases). Numerous (partly orphan) indications are covered by this new class of substances. Approximately ten years after the first substances of this class of medicines were authorized, patent protection will end within the next years. The following article covers clinical meaning and regulatory status of anti-cancer TKI and gives an outlook to what is expected from the introduction of generic anti-cancer TKI. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 18% |
| Student > Master | 10 | 15% |
| Student > Bachelor | 7 | 10% |
| Other | 6 | 9% |
| Researcher | 5 | 7% |
| Other | 13 | 19% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 21% |
| Agricultural and Biological Sciences | 13 | 19% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Medicine and Dentistry | 7 | 10% |
| Chemistry | 4 | 6% |
| Other | 4 | 6% |
| Unknown | 18 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2015.
All research outputs
#22,759,452
of 25,373,627 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,967
of 2,378 outputs
Outputs of similar age
#282,389
of 322,489 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#10
of 12 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,378 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,489 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.